# Trevogrumab and Garetosmab Trial for Muscle Preservation During Weight Loss Phase 2 study evaluates muscle-sparing therapies alongside semaglutide treatment for obesity management. - **Source:** [The Lancet – Online First](https://www.thelancet.com) - **Published:** 2026-11-11 - **Topic:** [health](https://brifing.si/c/health) - **Original article:** - **On Brifing:** https://brifing.si/s/c8bc3e90-8803-40d9-80f4-f62916f08490 ## Study Objective and Design The COURAGE trial investigated the efficacy of trevogrumab, an anti-GDF8 agent, in preserving lean muscle mass during weight reduction induced by semaglutide. Researchers conducted a two-part, phase 2, double-blind, placebo-controlled, randomized study. The primary goal was to determine if inhibiting GDF8 could mitigate the muscle loss typically associated with rapid weight loss. ## Trevogrumab Efficacy Results Trevogrumab demonstrated proof of concept as a generally well-tolerated strategy for maintaining lean body mass. Participants receiving this treatment showed positive outcomes regarding muscle preservation during their weight loss journey. This finding suggests that targeting GDF8 specifically may offer a viable pathway for patients undergoing GLP-1 receptor agonist-induced weight reduction protocols. ## Combination Therapy Outcomes The study also tested the addition of garetosmab, an anti-activin A inhibitor, to the trevogrumab regimen. While this combination led to further improvements in body composition and overall weight loss metrics, it failed to meet safety and tolerability standards. Consequently, the dual-inhibitor approach was deemed less favorable for clinical application in patients. ## Safety and Tolerability Profile Safety data indicated that while trevogrumab alone was well-tolerated, the combination therapy introduced significant challenges. Researchers observed that adding garetosmab compromised the safety profile of the treatment. These results highlight the delicate balance required when combining multiple biological inhibitors to enhance weight loss outcomes without inducing adverse effects in the patients. ## Muscle Mass and Metabolism Preserving lean mass is a critical concern during pharmacological weight loss, as muscle tissue is essential for metabolic health. The study focused on whether these specific inhibitors could protect muscle integrity while fat mass decreases. Maintaining muscle mass is hypothesized to support long-term metabolic stability and prevent common complications of rapid weight reduction. ## Future Research Directions Future investigations are necessary to determine if the improved body composition observed during these trials translates into tangible benefits for physical function. Researchers must clarify whether preserving lean mass directly correlates with better metabolic health outcomes. Further studies will likely focus on optimizing the dosage and safety parameters of GDF8 inhibition strategies. ## Clinical Implications for Obesity Obesity management often involves GLP-1 receptor agonists, which can lead to significant muscle loss alongside fat reduction. This trial provides a foundational step toward developing adjunct therapies that protect muscle tissue. By addressing the specific biological pathways of muscle wasting, clinicians may eventually offer more comprehensive weight management solutions for patients. ## Context of Biological Inhibition The trial underscores the complexity of targeting growth factors like GDF8 and activin A in human subjects. While biological inhibitors show promise in preclinical models, their clinical application requires rigorous testing for safety. The COURAGE trial serves as a vital reference for future pharmacological interventions aimed at refining body composition during obesity. ## Sources covering this story - https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01953-7/fulltext?rss=yes — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._